IPO - Oculis Holding AG

Form Type: 424B5

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000119312525027247

Filing Summary: Oculis Holding AG is offering 5,000,000 ordinary shares at an offering price of $20.00 per share, aiming to raise approximately $100 million before underwriting commissions. The company focuses on developing innovative drug candidates for ophthalmic diseases. Their leading asset, OCS-01, is in Phase 3 development for diabetic macular edema. Additionally, the firm has announced positive topline results from its Privosegtor Phase 2 ACUITY trial, which evaluated a neuroprotective product candidate. As of January 2025, Oculis Holding AG reported an estimated $105 to $110 million in cash and short-term investments. The underwriters expect to deliver the shares on or about February 18, 2025. The company's stock symbol is 'OCS' on Nasdaq and Nasdaq Iceland. The offering is part of a broader registration statement and aims to accelerate clinical development and general corporate purposes. The company presents itself as an 'emerging growth company' and a 'foreign private issuer', which entitles it to certain regulatory exemptions. Investors are urged to review risk factors associated with the offering and the company's operations before investing.

Document Link: View Document